Safety and immunogenicity results from the HVTN 124 study will be presented by WHV at the Full Group meeting of HVTN.
HVTN 124 is a phase 1 clinical trial conducted by NIH-funded HIV Vaccine Trials Network, testing the safety and immunogenicity of PDPHV-201401, WHV’s preventive HIV vaccine candidate. The trial recently completed and immunogenicity is being assessed by both HVTN and WHV. The preliminary data from these analyses supports the advancement of this vaccine candidate to further clinical testing.
HVTN leadership invited WHV to present the results of the trial at its annual 2021 Full Group Meeting. The meeting will be held virtually on May 5-7, 2021 and will cover the progress in immune-mediated HIV prevention approaches including vaccines and passive immunizations.
